ArticleMedicine international
Cardiovascular disease treatment and hyperkalemia: A report of three cases.
Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renin-angiotensin-aldosterone system inhibitors (RAASi) are primarily used for the treatment of hypertension and diabetic/non-diabetic reno-cardiovascular diseases. The present study describes the cases of 3 patients with hyperkalemia that occurred during RAASi therapy and describes the therapeutic approach used for this serious complication. The clinical/laboratory findings of hospitalized patients with hyperkalemia within a short time period (within 30 days) and treatment were recorded. Acute hyperkalemia developed due to angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) and spironolactone in 3 patients, whose cases are reported herein. Insulin glucose infusion (IGI) + salbutamol + potassium binders were used for the treatment of severe hyperkalemia. Acute kidney injury (AKI) regressed in all patients. Hyperkalemia was corrected within 6 h in 1 patient who was treated with sodium zirconium cyclosilicate in addition to IGI. On the whole, the present study demonstrates that hyperkalemia may be symptomatic/asymptomatic and may develop during the earlier or later period of RAASi therapy for cardiovascular-renal disease, particularly in older patients. AKI improved with the correction of hyperkalemia and the discontinuation of ACEi/ARB and spironolactone. Sodium zirconium cyclosilicate may be the preferred treatment in emergency cases of hyperkalemia due to its rapid effects. On the other hand, sodium glucose co-transporter 2 inhibitors and non-steroidal mineralocorticoid receptor antagonists may also be used to avoid the development of hyperkalemia in patients undergoing RAASi therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.